Lovelace Biomedical

Lovelace Biomedical is a non-profit, non-clinical contract research organization (CRO) based in Albuquerque, NM, USA. Specializing in toxicology, pharmacology, and disease modeling, Lovelace Biomedical supports the research and development of pharmaceutical companies.

This section details the features of Lovelace Biomedical's non-clinical studies, an example of a pathological model, and case studies.

Lovelace Biomedical's Contract Non-clinical Trial Services Features

Extensive experience and strengths in specialized fields

With a history of scientific research since its founding in 1947, we are committed to non-clinical trials utilizing our multidisciplinary expertise. We are particularly strong in the fields of respiratory diseases, infectious diseases, gene therapy, and neuroscience.

We conduct studies in compliance with FDA Good Laboratory Practice (GLP) standards, and our experienced scientists provide objective data on efficacy and toxicity mechanisms to support the drug's transition to clinical development.

Responsiveness through large scale, advanced research facilities

Large facility in New Mexico with over 100 acres and 300,000 square feet of laboratory space (as of February 2026 survey); laboratories with advanced biosafety levels, including ABSL-3, and facilities to accommodate a variety of animal species, including primates The facility is also equipped with facilities that can accommodate a wide variety of animal species, including primates. We provide a research environment that can flexibly accommodate a variety of non-clinical programs, from gene therapy to infectious disease control, under appropriate management systems.

An example of Lovelace Biomedical's pathological model

model of pathogenesis of infectious diseases

In our COVID-19 research, we utilize a variety of animal models, including humanized ACE2 transgenic mice, hamsters, ferrets, and macaque monkeys, to measure physiological data such as respiratory rate and ventilation rate. and other physiological data, we are developing pathological models to reproduce disease progression in clinical practice.

Respiratory disease and gene therapy models

In respiratory disease modeling, we have models for asthma and acute respiratory distress syndrome (ARDS), and we use specialized equipment for drug delivery by inhalation to evaluate lung function in detail.

In the area of gene therapy for rare diseases, we have created complex disease models, such as genetically engineered mice, and are using real-time PCR to analyze in vivo distribution and conduct detailed safety evaluations.

Lovelace Biomedical's Non-clinical Case Studies

Support for development of inhalation powder drug for lung cancer

In one case, we assisted with process optimization and modeling in the development of an inhalation dry powder formulation of 5-azacytidine (5-AZA) for the treatment of metastatic lung cancer. Target clinical doses were determined based on systemic dosing data in humans and nonclinical data comparing intravenous and inhaled dosing. By setting the drug load to 20%, we have helped to achieve a product profile that improves systemic exposure and tumor shrinkage.

Safety evaluation of cannabidiol inhalation

This case study evaluated the biological response to inhalation of cannabidiol (CBD) and propylene glycol (PG) in Sprague-Dawley rats, which were subjected to nasal inhalation of aerosols of CBD and PG over a 14-day period. Through monitoring of body weight changes, clinical signs, and hematological pathology evaluation, the safety profile of CBD inhalation was determined, contributing to efficient product delivery and risk assessment.

Lovelace Biomedical Company Information

Lovelace Biomedical is a non-profit, non-clinical contract research organization with a history of nearly 70 years. With its vast facilities and equipment, Lovelace Biomedical provides comprehensive support to pharmaceutical companies and research institutions from drug development to regulatory filings.